focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
You yourself said 500 quid a couple of months ago and been deramping since so don't know where you got the extra 6 from. And 10 comments a day, don't make me laugh. You're in here from 7am in the morning to past midnight, you do more than 10 in your first few hours on an average day! Anyway, keep posting. The 500 is dwindling by the day.
Well done, you made 500 quid, to quote Your Own bragging a couple of months ago. Took you 4 months, 24/7 posting on here to make that. Thats just over 25 quid a week for 7 days work, near enough 24 hours a day. What a loser Haha. This is why I want you to waste asmuch of your time in here as possible and make you really work for every little scrap of research so the longer u spend without taking a position the more that 25quid a week dwindles. Btw I don't post on advfn. 25 quid a week loser. Hahaha
Ralphie, let him find it himself. He has only one agenda here and that to do whatever he can to get the price as low as possible, might aswell make him work hard for it. With any luck he'll only miss his entry again in the vain hope of making another few hundred quid and in the process have wasted even more of his life in here for nothing!
Good, I hope you spend many more hours trying finding it you timewaster
It's a snowball effect for Dave, he prob sold at a loss, became bitter, deramper for months to try make it back, after spending so much time deramping he only went and missed his entry which it turn made him even more bitter now hes deramping again because he's too heavily invested by way of time spent deramping to give up now. haha. Desperate Dave the world's worst day trader. Loser
What matters is the value of the contract, that is what will dictate price. Pre clinical can be in the 30- 75k range as seen recently. Clinical is ten times that, in this case 350-700K. And if it's for a few drugs then multiple that again. And remember there's several leads being pursued so multiply that again. Strong potential. Read the RNSs
Horsford, have a read of this article from May; "To fully commercialise the TexRAD product it must be granted a CE Mark, European certification for the technology. It was on track to get this by the end of May 2017 but then it identified several new enhancements that will improve performance. While that is good news, the discoveries mean that the award of the CE mark will be delayed.." http://www.proactiveinvestors.co.uk/companies/news/178016/feedback-plc-s-eye-on-the-prize-a-ce-mark-for-texrad-178016.html
It's not a case of nudge nudge wink wink but rather those the company are liaising with on the other end will be able to keep them appraised of where they are on the path to approval and expected timescales. As for what happened a year ago the company withdrew the application to resubmit with product enhancements so it wouldn't have to go thru a second round. It's not the case here that the approval has been held up for 6months but that a revised application was.submitted which naturally will.kick the process back to the beginning again hence the additional time
I think that the recent statements by the bod around expected CE approval are genuine given the explicitness Of The timeframe and the proximity to it. I believe the problem now is one of lack of publicity, if the investment proposition can be articulated cohesively and widely the appreciation in SP will be seen given the compelling product here. Just need to get the word out
Great points Scott. I think how the company chooses to communicate deals to the market can to some degree be influenced by Shareholders given the likes of TB are on board who will likely be open to taking on board shareholder feedback. I may well be contacting them after the CE approval requesting regular updates on this rather than having to wait for quarterly or half yearly updates.
Expected within weeks. Company is already in discussions with a major distributor. Rich newsflow period over the short term with many share price catalysts all at low risk as product has already been proven out and tested with better than expected success rates
Some good points made here; https://stockpains.blogspot.co.uk/2017/09/fbdu-research-note.html?m=1
FBDU flying today, as we know at only 1% of the market this is worth �1.87 per share fully diluted. Current levels we are really just at the beginning, in the foothills of the potential here. CE approval expected within weeks and then commercial sales begin in Europe, India and China with FDA approval to follow.
I think the 20P could come a lot sooner than that Wisha, given the strong newsflow period were in, low number of shares in issue and in free float. It ticks up with almost every buy as seen this morning and Friday.
Theres currently 64,786,721 shares in issue. There is currently �313,800 CLNs outstanding (see RNS dated 3rd July 2017) convertible at a price of �0.015 per share (see RNS dated 20th Nov 2015). If all these CLNs are converted that would mean the admission of an additional 20,920,000 shares (but with it would bring �313,800 of additional funds into FBDU coffers). This would bring total shares in issue to 85,706,721 with nothing else outstanding. By AIM standards that is still super low and using the calculations on my previous post would be 210M / 85,706,721 instead. This would equal $2.45 per share which in � terms would make it �1.87 per share. Thats fully diluted with nothing outstanding. Still huge upside from the current 4.3p per share.
Market in treatment of kidney stones expected to reach $3 BN. FBDU is software based, meaning minimal costs thus high margin. If FBDU captures just 1% of that market that's potentially $30M a year in revenue. According to investopedia gross margin on software companies is 90%. Let's say net margin is 70%, that makes it $21M profit a year. On PE of 10 ( which is low for a software company) that's $210M valuation of the company. In shareprice terms on a shares in issue of 64M that's a shareprice of $3.28. Convert that to �, it's �2.50 per share. All that's at 1% market share. No ramping, just facts. http://www.nbc-2.com/story/36444277/kidney-stones-market-accruals-reaches-to-usd-3000-million-with-4-of-cagr-by-2023
At a 2M mcap what is left to be destroyed?